“The present problem has uncovered some structural weaknesses in the EU’s medicines offer chain along with a higher dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides claimed. She suggested that supply chain concerns be addressed within an EU pharmaceutical strategy predicted to be introduced by t